74 results about "Specific immunoglobulins" patented technology

A pharmaceutical composition for treating allergy is described. The composition comprises as an active ingredient a recombinant polyclonal antibody or a mixture of different monoclonal antibodies capable of reacting with or binding to an allergen together with one or more pharmaceutically acceptable excipients. The composition may be used topically as a solution, dispersion, powder, or in the form of microspheres. The polyclonal antibody is preferably a recombinant polyclonal antibody produced by phage display technology. The pairing of specific immunoglobulin variable region light chain and heavy chain maintained from the original polyclonal immune response or selected by panning using the allergen in question is preferably maintained by bulk transfer of the pairs into an expression vector.

The invention is directed to novel CDRs and immunoglobulin products that bind to A33 antigens and methods for their use. The invention also involves a method for making humanized antibodies, using a rabbit as a host animal, and phage display library methodologies, and the antibodies themselves. The methodology is useful, for example, in generating humanized antibodies against molecules associated with cancer, such as A33, which is associated with colon cancer.

An anti-IL-23 specific human Ig derived protein is useful in therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably includes one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.

The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides. The present invention relates to multivalent (eg, multispecific) antibodies, antibody chains and polypeptides, as well as heavy chain-only antibodies (H2 antibodies) that are devoid of light chains. The invention further relates to the selection, maturation and production of these in vivo in non-human vertebrates and non-human vertebrate cells. To this end the invention also relates to such non-human vertebrates and cells. The invention also relates to the provision of means to produce and select heavy chain-only antibodies and heavy chains comprising variable domains that have undergone affinity maturation.

Compositions and kits comprising combinations of β-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which β-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.

The invention discloses a production method of an immunoglobulin compound preparation for especially preventing and treating porcine diarrhea, and relates to the field of veterinary drugs and feed additives. The production method comprises the following steps: adding part of extracts or powder and the like to specific immunoglobulin or a substance which is not extracted and contains the specific immunoglobulin according to a certain proportion; and then evenly mixing to obtain the immunoglobulin compound preparation. By compositing the advantages of the immunoglobulin extract or powder, a novel antibiotic substitute is formed, thereby achieving the purposes of treating both symptoms and causes, accelerating the rehabilitation speed of a diarrheal animal, preventing and treating porcine diarrhea and meanwhile lowering cost; and the immunoglobulin compound preparation is a safe and hormone-free green product with special good effect on porcine diarrhea. The immunoglobulin compound preparation is taken as a feed additive or mixed with water and drunk. The immunoglobulin compound preparation is especially applicable to prevention and treatment of porcine diarrhea and also suitable for diarrheal diseases of animals such as various poultry, livestock and the like.

The invention discloses methods for preparing and isolating anti-H1N1 specific immunoglobulin of egg yolk (IgY). The IgY is prepared by the following steps: 1. expressing HA segments of H1N1 by genes to obtain the antigen of H1N1; 2. carrying out injection immersion on the laying hens with the prepared H1N1 antigen to obtain anti-H1N1 immune eggs; and 3. extracting the crude products of the anti-H1N1 specific IgY and purifying and filtering the crude products, thus obtaining the finished anti-H1N1 IgY. The obtained anti-H1N1 IgY has low cost, high yield and high specificity and can be used for preparing various preparations having the functions of preventing and treating H1N1.

The invention relates to a paper based sensor capable of detecting allergic reactions as well as preparation and application of the paper based sensor and belongs to the field of paper based sensors.The allergic reaction refers to abnormal and excessive immune response caused by the reasons that a specific immunoglobulin (IgE) antibody is produced when the body is stimulated by a certain antigenand the IgE can be bound to an IgE specific receptor on the surface of mast cells and basophilic granulocyte. Therefore, the IgE in serum is an important marker for detecting the allergic reaction. Ni-NTA can be specifically bound with a His label, thereby realizing affinity purification of proteins. The paper based material has the advantages of being cheap, portable, high in selectivity and biocompatibility and the like, so the paper based sensor containing the Ni-NTA is prepared and can be firmly bound to an allergen containing the His label, and qualitative detection of the immune globulinis realized. The paper based sensor has important significance for rapidly and sensitively detecting the allergic reactions.

The invention concerns a new medicinal product for the treatment of chikungunya, i.e a concentrate of chikungunya-specific immunoglobulins, as well as its process of preparation.

Present invention is directed to materials and methods useful in diagnosing gut derived advanced glycation end-products (“Fru-AGEs”) associated with asthma, juvenile arthritis and other pro-inflammatory chronic diseases. Fru-AGEs arise from the interaction [fructosylation] between elevated gastro-intestinal excess free fructose and other food/bio-molecules including peptides, proteins, lipids, lipo/glycoproteins and others in the digestive tract. Such Fru-AGEs may further interact with moieties of the systemic circulation of those at risk [fructose malabsorbers], i.e. with acute phase proteins, heat shock proteins, immunoglobulins, esRAGE, and sRAGE. Specification describes methods to identify and/or make such excess-free-fructose derived immunogens, i.e. Fru-AGEs, Fru-AGE-haptens, Fru-AGE immune complexes, and to make monoclonal/polyclonal antibodies to such bio-molecules for use as therapeutic agents and/or for use in immuno-assays including fluorescence enzyme immunoassay, microarray specific immunoglobulin/antibody testing, fluids detection [blood and urine] of GI Fru-AGE/haptens/immune-complexes.

The peroral freeze dried specific yolk immune globulin preparation includes specific immune globulin, excipient and solute in solvent. The preparation process includes preparing specific pathogen antigen; adding incomplete Folin reagent in the same amount as the antigen for fully emulsification to obtain immunogen; immunizing the layer with the immunogen; extracting specific yolk immune globulin from the egg of the layer; mixing the specific immune globulin, the excipient and the solvent to obtain mixture liquid; freeze drying the mixture liquid to produce the peroral freeze dried specific yolk immune globulin preparation. The preparation has the specific yolk immune globulin with less denaturation and maintained natural activity, and may be used in preparing medicine, food or health article for treating digestive tract disease caused by pathogenic microbe.

The invention discloses lactobacillus reuteri capable of alleviating allergic asthma and application thereof and belongs to the technical field of medicines. The lactobacillus reuteri has an effect ofrelieving allergic asthma, which is embodied by: (1) significantly reducing lung inflammation in mice with allergic asthma; (2) significantly inhibiting the generation of dust mite specific immunoglobulin IgG1 in serum of allergic asthma mice; (3) significantly reduced the contents of IL-5 and IL-13 in alveolar lavage fluid of mice with allergic asthma; (4) significantly reducing the content of IL-17A in alveolar lavage fluid of mice with allergic asthma, and thus the lactobacillus reuteri has great application prospects in the preparation of products for preventing and/or treating allergic asthma.

A process is disclosed which enables the establishing of comprehensive immunoglobulin-specific reaction profiles of subjects with disorders of the immune function by the individual V gene repertoire of Ig-expressing B cells. The process comprises the isolation of B cells from body fluids, the isolation of individual B cells and their genetic material, the amplification of nucleic acids coding the variable regions of an antibody expressed by a B cell, the recombinant preparation of antibodies by expressing the amplificates, and the determination of the binding

The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (SIT) in a patient. The present invention also provides for the measurement of allergen specific IgG and IgE in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen. The invention also provides methods for determining whether a patient suffering from an allergy is responsive to therapy with one or more therapeutic antibodies specific for the allergen.

A method of preparing immunoglobins with high valence and high specialty against respiratory syncytial virus and adenovirus. It comprises culturing respiratory syncytial virus and adenovirus with Hep-2 cell strain, Hala Strain, preparing virus antigen, or preparing protective antigens according to sequences of respiratory syncytial virus and adenovirus by the genetic engineering technology; then,centrifuging the prepared virus antigens and getting purified antigens, or concentrating antigens by 20úÑ sucrose, or purifying antigens by chromatographic absorbing columns, screening high-valent immunoglobins against respiratory syncytial virus and adenovirus, and neutralizing virus in viro; finally extracting immunoglobins from bloods containing high-valent immunoglobins against respiratory syncytial virus and adenovirus by a low-temperature alcohol method or ion exchanging chromatography and so on.